Share-Based Compensation (Details Narrative) (Mymd Pharmaceuticals Inc.) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Nov. 10, 2020 |
Dec. 31, 2020 |
Dec. 31, 2016 |
|
| Number of shares cancelled | |||
| Mymd Pharmaceuticals Inc. [Member] | |||
| Number of shares cancelled | 31,300,000 | ||
| Options expiration period | 2 years | ||
| Option modification | $ 2,009,145 | ||
| Unamortized discount | $ 880,020 | $ 1,457,882 | |
| Mymd Pharmaceuticals Inc. [Member] | 2016 Stock Incentive Plan [Member] | |||
| Number of common stock reserved for issuance | 50,000,000 | ||
| Number of shares cancelled | 31,300,000 |
| X | ||||||||||
- Definition Aggregate number of common shares reserved for future issuance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of debt discount. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition An excess of the fair value of the modified award over the fair value of the award immediately before the modification. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|